CKD Bio Corp. (KRX:063160)

Market Cap	103.14B -19.1%
Revenue (ttm)	159.93B +3.6%
Net Income	-23.13B
EPS	-4,216.38
Shares Out	5.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,616
Average Volume	18,015
Open	18,870
Previous Close	18,800
Day's Range	18,620 - 18,870
52-Week Range	18,390 - 27,650
Beta	0.63
RSI	39.97
Earnings Date	n/a

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 519
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 063160

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.